Opinion|Videos|March 4, 2024
Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
The claudin 6–targeted antibody-drug conjugate ixotatug vedotin showed antitumor activity in recurrent germ cell tumors, including after transplant.
The sacituzumab govitecan, enfortumab vedotin, and zimberelimab triplet produced early, durable responses in untreated metastatic urothelial cancer.
Efficacy outcomes in KEYNOTE-905 were consistent with a contribution of both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC.
Advertisement
Advertisement
Trending on OncLive
1
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
2
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
3
The OncFive: Top Oncology Articles for the Week of 10/25
4
NCCN Guideline Inclusion Broadens Access to Brigatinib in NF2-Related Schwannomatosis
5